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Abstract
Mesenchymal stem cells (MSCs) are one of the most attractive cell types for cell-based
bone tissue repair applications. Fetal-derived MSCs and maternal-derived MSCs have
been isolated from chorionic villi of human term placenta and the decidua basalis attached
to the placenta following delivery, respectively. Chorionic-derived MSCs (CMSCs) and
decidua-derived MSCs (DMSCs) generated in this study met the MSCs criteria set by Inter-
national Society of Cellular Therapy. These criteria include: (i) adherence to plastic; (ii)
>90% expression of CD73, CD105, CD90, CD146, CD44 and CD166 combined with <5%
expression of CD45, CD19 and HLA-DR; and (iii) ability to differentiate into osteogenic, adi-
pogenic, and chondrogenic lineages. In vivo subcutaneous implantation into SCID mice
showed that both bromo-deoxyuridine (BrdU)-labelled CMSCs and DMSCs when implanted
together with hydroxyapatite/tricalcium phosphate particles were capable of forming ectopic
bone at 8-weeks post-transplantation. Histological assessment showed expression of bone
markers, osteopontin (OPN), osteocalcin (OCN), biglycan (BGN), bone sialoprotein (BSP),
and also a marker of vasculature, alpha-smooth muscle actin (α-SMA). This study provides
evidence to support CMSCs and DMSCs as cellular candidates with potent bone forming
capacity.
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Introduction
Mesenchymal stem cells (MSCs), which are also referred to as multipotent stromal cells, are
found in many tissues. MSCs are capable of multipotent differentiation, allowing them to con-
tribute to bone regeneration and repair since MSCs can readily differentiate into osteocytic lin-
eages [1]. Moreover, MSCs are readily isolated, their numbers can be greatly expanded in
culture, cryopreserved for later use, and importantly, they display low immunogenicity, are
immunomodulatory and have a good safety profile. According to the International Society for
Cellular Therapy (ISCT), MSCs must; (i) adhere to untreated plastic surfaces; (ii) express
CD105, CD73, and CD90 but not CD34, CD14, CD19, CD11b, CD79α or HLA-DR, and (iii)
differentiate into osteogenic, adipogenic and chondrogenic lineages in vitro [2].
The human term placenta is an abundant, readily accessible and non-controversial source
of MSCs. MSCs have been isolated from fetal derived placental tissues including the amnion,
chorion and chorionic villi, and from maternal derived tissues that are attached to placental tis-
sue following delivery i.e. the decidua parietalis and decidua basalis [3–7]. The peripheral
region of the placenta on the maternal side that is in contact with the uterine wall (called the
basal plate) comprises the chorionic villi on one side, and maternal decidua basalis on the
other. Following delivery of the placenta, the decidua basalis remains attached to the maternal
side of the placenta. Thus, careful preparation and characterization needs to be carried out to
confirm the maternal origins of decidua basalisMSCs (DMSCs) and the fetal origins of the
chorionic villous MSCs (CMSCs). As such, in addition to the criteria stipulated by the ISCT,
Parolini et al. proposed that CMSCs should have<1% maternal cells in the population [8, 9].
The significant issue of the presence of maternal cells in human placental MSCs cultures was
reviewed recently [10]. Therefore, the first aim of this study was to isolate and characterize
CMSCs and DMSCs according to the criteria described above and to confirm the respective
fetal and maternal origins of these cells. This characterization was an essential prerequisite to
the use of CMSCs and DMSCs for in vivo assays.
While studies have reported osteogenesis by CMSCs and DMSCs in vitro, bone formation
in vivo has not been investigated. Such studies are essential for evaluating the functional capac-
ity of CMSCs and DMSCs and their potential for clinical applications. Therefore, we initiated
the study using a mouse model of ectopic bone formation to explore the possibility that isolated
human CMSCs and DMSCs were capable of regenerating ectopic bone-like structure in vivo.
The orthotopic bone formation assay is commonly used to study osteogenesis in vivo. Com-
pared to the orthotopic assay, the ectopic bone forming assay has unique advantages since there
is no requirement for bone cytokine stimulation and cell-to-cell interaction with endogenous
bone-forming cells [11]. In addition, a variety of ectopic locations can be used for cell implanta-
tion, including subcutaneous and intramuscular sites and the kidney capsule [11]. Subcutaneous
implantation is the simplest experimental model of ectopic bone formation. Mouse models are
preferable and most widely used due to their low cost, loose skin folds that can accommodate
large implants, and the availability of immunodeficient mice that will accept implanted human
cells. Another important consideration is the lack of naturally occurring bone-forming stem
cells within the intradermal compartment and therefore newly-formed bone can be confidently
attributed to the exogenous stem cells. The most pertinent concern regarding subcutaneous
implantation is the lack of robust bone growth which may be due to poor blood flow. However,
subcutaneous bone formation can be stimulated by incorporating hydroxyapatite and tricalcium
phosphate (HA/TCP) together with stem cells. HA/TCP are currently used as bone graft substi-
tutes, are biocompatible and form bonds between bone and ceramic implants [12]. The second
and principal aim of this study was to evaluate in vivo bone formation capacity of CMSCs and
DMSCs following subcutaneous implantation together with HA/TCP.
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Materials and Methods
Tissue collection
Placental samples were collected from healthy women with normal pregnancies following elec-
tive Caesarean section or vaginal delivery at term (n = 6). The placental tissue had no obvious
signs of calcification, infarcts or meconium staining. Exclusion criteria were women who
smoked or had a twin or triplet pregnancy, drug dependency, intrauterine infection, prolonged
rupture of the fetal membranes or placental abruption. Informed written consent was obtained
from all participants before delivery. The study was approved by the Royal Women’s Hospital
Human Research Ethics Committee.
Isolation of CMSCs
CMSCs were isolated using the explant method as described previously [7] with the following
modifications. Briefly, an incision was made through the fetal membranes near the umbilical
cord insertion site and 1 g of chorionic villous tissue was obtained from approximately 1–2 cm
below the chorionic plate. Pieces of chorionic tissue with typical villous morphology were
cleaned with a 21 gauge needle under a dissecting microscope to remove non-villous tissue.
Cleaned villi were finely diced and digested in 0.25% trypsin for 40 min at 37°C. The trypsin
was inactivated with FBS and tissues were washed in PBS. The digested villi were cultured in
Amniomax C100 complete medium (Life Technologies) in 25 cm2 tissue culture flasks main-
tained at 37°C in a humidified 5% CO2 incubator. After 7 days, villous tissues were removed
from the flask and the adherent cells arising from the explants (P0 cells) were grown until at
least 80% confluent before expanding to reach P5.
Isolation of DMSCs
We have previously reported the isolation of DMSCs from the decidua basalis adhering onto
the maternal side of the placenta [13]. About eight grams of placental tissue was dissected from
the basal plate, washed four times in PBS, finely minced and digested in trypsin (0.25%; Life
Technologies, CA, USA) and DNAse 1 (50 μg/mL; Worthington, NJ, USA) at 4°C overnight.
Fetal bovine serum (FBS; Thermo Scientific, MA, USA) was added to inactivate the trypsin and
the digest was centrifuged at 200g for 5 min. The pelleted tissue was digested in type 1 collage-
nase (10 mg/mL; Worthington) and DNAse 1 (50 μg/mL, Worthington) for 30 min at 37°C
and strained through a 100 μm stainless steel sieve. The filtrate was layered over Histopaque
(Sigma-Aldrich, MO, USA) and separated by density gradient centrifugation at 400g for 30
min. Mononuclear cell layers containing the DMSCs were aspirated and centrifuged at 200g
for 5 min. DMSCs were maintained in α-MEMmedium (Sigma-Aldrich) with 10% FBS, peni-
cillin/streptomycin (100 U/mL and 100 mg/mL, respectively; Life Technologies) and 2 mM L-
glutamine (Sigma-Aldrich). P0 DMSCs were passaged after reaching 80% confluence and cells
were expanded up to P5.
Fluorescence in situ hybridisation (FISH)
FISH was used to determine whether the DMSCs were maternal and the CMSCs fetal in origin
as described elsewhere [6, 13]. Briefly, term placentae delivered from pregnancies carrying
male babies (n = 3) were used to prepare DMSCs and CMSCs. Cells were lifted with TrypLE
Express, washed in Hank’s buffered saline solution (HBSS; Life Technologies) and placed on
poly-L-lysine coated glass slides (Thermo Scientific). After fixing in 3:1 methanol to acetic acid
solution at room temperature (RT), cells were hybridized with labelled chromosome X
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(Spectrum Green) and chromosome Y (Spectrum Orange) probes (Abbott Molecular, MO,
USA). Approximately 200 cells per slide were examined.
Flow cytometry
To determine whether expanded cells expressed positive and negative markers characteristic of
MSCs, cells were analyzed by flow cytometry for CD73, CD105, CD90, CD146, CD44 and
CD166 and the absence of CD45, CD19 and HLA-DR. Cells were incubated with each of the
primary antibodies or equivalent concentrations of matched isotype controls (Table 1) as
described previously [13]. Cells were then washed in HBSS containing 2% FBS and centrifuged
at 1000 rpm for 5 min. Cell pellets were resuspended in 500 μL of HBSS with 2% FBS and 1 μg/
mL DAPI (Sigma-Aldrich). The cells were analyzed on a LSRII flow cytometer with FACS Diva
software (BD Biosciences, CA, USA).
In vitro differentiation into mesenchymal lineages
Differentiation of DMSCs and CMSCs into adipogenic, osteogenic, and chondrogenic lineages
was assessed in vitro. In vitro differentiation was carried out with bullet kits as described [5, 6,
13]. Adipogenic and osteogenic differentiation was carried out in Mesencult basal medium
together with the respective differentiation supplements according to manufacturer’s instruc-
tions (Stem Cell Technologies, BC, Canada). Chondrogenic differentiation was carried in
DMEM/F12 medium (Life Technologies) with 1% ITS and chondrogenic supplements (both
from R&D Systems, MN, USA) according to the manufacturer’s instructions. Cells were
stained with Oil Red O solution, Alizarin Red solution and Safranin O (Sigma-Aldrich) to visu-
alize adipogenesis, osteogenesis and chondrogenesis respectively.
In vivo ectopic bone formation assay
CMSCs and DMSCs (n = 3 each) were expanded to reach approximately 1x107 cells per sample
(P2-P3). Approximately 2x106 MSCs from each donor were mixed with 40 mg hydroxyapatite/
tricalcium phosphate (HA/TCP) ceramic particles (Zimmer Inc., IN, USA) and then subcuta-
neously transplanted into the dorsal surface of eight-week-old SCID mice (National Institutes
of Health-bg-nu-xid; Harlan Sprague-Dawley, IN, USA) as described previously [14, 15]. Each
Table 1. Antibodies used for characterizing CMSCs and DMSCs by flow cytometry.
Antibodya Conjugate Clone Volume / 100μl Manufacturer
CD45 APC-Cy7 2D1 1μl BD Biosciences
CD73 PE AD2 1μl BD Biosciences
CD105 APC SN6 0.5μl eBioscience
CD90 PE 5E10 0.25μl BD Biosciences
CD146 PE P1H12 1μl BD Biosciences
CD44 PE G44-26 1μl BD Biosciences
CD166 PE 3A6 1μl BD Biosciences
HLA-DR APC G46-6 1μl BD Biosciences
CD19 APC-Cy7 SJ25C1 0.25μl BD Biosciences
IgG1 isotype control PE MOPC-21 1μl BD Biosciences
IgG2a isotype control APC G155-178 1μl BD Biosciences
IgG1 isotype control APC-Cy7 MOPC-21 0.25μl BD Biosciences
a anti-human antibodies raised in mice.
doi:10.1371/journal.pone.0141246.t001
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mouse received two implants. These procedures were performed in accordance with guidelines
of an approved small-animal protocol (South Australia Pathology Animal Ethics Committee
#139/09). After 8 weeks, the implants were removed, fixed in 10% formalin overnight at 4°C,
and then decalcified for 2 weeks in 0.5 M EDTA, prior to paraffin embedding. For histological
analysis, 5 μm sections of the implants were prepared and stained with haematoxylin and eosin
(H&E). Expression of the specific osteogenesis markers osteocalcin (OCN), osteopontin
(OPN), biglycan (BGN), and bone sialoprotein (BSP), were analyzed by immunohistochemis-
try using previously published methods [16]. The implanted cells were labelled with BrdU at
24 and 48 hrs prior to implantation to evaluate the localization of the transplanted cells. Immu-
nohistochemical staining using an anti-BrdU antibody was carried out as previously described
[17].
Results
Isolation and expansion of CMSCs and DMSCs
CMSCs were isolated using the explant method [5, 7]. CMSCs migrated from the explants
approximately 7 days after plating. P0 and expanded CMSCs exhibited the characteristic the
fibroblast-like morphology of MSCs (Fig 1Ai). DMSCs isolated from the decidua basalis
attached to chorionic villi of term placentae adhered onto tissue culture flasks within 24 h of
plating. Consistent with previous findings [18–20], P0 DMSCs were initially heterogeneous
and became more homogeneous following expansion and had the fibroblastic morphology
characteristic of MSCs (Fig 2Ai). Given that CMSCs and DMSCs were morphologically indis-
tinguishable after passaging, it was crucial that CMSCs and DMSCs used in these experiments
were well-characterized with respect to their surface markers expression, origin, and differenti-
ation potential.
Phenotypic characterization of CMSCs and DMSCs
CMSCs and DMSCs at P3-P5 were analyzed by flow cytometry for cell surface markers present
on expanded MSCs [2, 9]. More than 90% of CMSCs (Fig 1B and DMSCs (Fig 2B) expressed
the MSC markers CD90, CD146, CD166, CD44, CD73 and CD105, while<5% were CD45,
CD19 and HLA-DR positive. These findings were consistent with the expression profile stipu-
lated for MSCs. Cells beyond P5 were not analyzed since studies have reported that MSCs
undergo cell death or senescence after five passages [4, 21–23].
Given the risk of cross contamination between fetal and maternal cells, firstly we analyzed
CMSCs and DMSCs by FISH to verify that pure cell populations had been isolated. CMSCs
and DMSCs were isolated from placentae of women delivering a male baby, and approximately
200 cells of each type were analyzed for signals in interphase nuclei using X/Y chromosome
probes. CMSCs showed the XY phenotype (Spectrum Green and Orange labelled chromo-
somes, respectively) and were therefore male (Fig 1Aii). Evaluation of 200 interphase nuclei
revealed that CMSCs used in this study had 94% XY (6% XXYY), 100% XY, and 99.5% XY
(0.5% XXYY). Two Spectrum Green labelled X chromosomes were visible in DMSCs and
therefore DMSCs were female (Fig 2Aii). Evaluation of 200 interphase nuclei showed that
DMSCs used in this study had 100% XX, 92.5% XX (7.5% XXXX), and 99% XX (1% XXXX).
Cases of tetraploidy were always XXYY from fetal CMSCs and XXXX from maternal DMSCs
preparations. Tetraploidy is a common artefact of cell culturing and does not preclude the use
of cell preparations for further analysis [24].
Differentiation of expanded CMSCs and DMSCs into osteogenic, adipogenic and chondro-
genic lineages was also examined to further verify their in vitroMSC properties. Alizarin Red
stained calcium deposits indicative of bone formation were visible in CMSCs maintained in
Ectopic Bone Formation by Placenta-Derived Mesenchymal Stem Cells
PLOS ONE | DOI:10.1371/journal.pone.0141246 October 20, 2015 5 / 13
Fig 1. CMSC phenotypic characterization. A. (i) Bright field microscopy image of CMSCs at P0. Magnification is 100X and scalebar is 100 μm. (ii) CMSCs
from placentae of male newborns were analyzed using interphase FISH on MSC nuclei. CMSCs showed one chromosome X (Spectrum Green) and one
chromosome Y (Spectrum Orange) signals. Cell nuclei were stained blue with DAPI. Magnification is 630X. B. Primary CMSCs cell surface markers
expression. Histograms of representative primary CMSC at P3 depicting the expression of CD90, CD146, CD166, CD44, CD73, CD105, CD45, HLA-DR,
and CD19. The red histogram shows the MSCmarker antibody staining while the white histogram shows the corresponding isotype control antibody staining.
PE: phycoerythrin dye, APC: allophycocyanin dye, APC-Cy7: allophycocyanin-Cy7 dye. C. Representative photomicrographs showing CMSCs
Ectopic Bone Formation by Placenta-Derived Mesenchymal Stem Cells
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osteogenic induction medium (Fig 1Ci). Oil Red O stained lipid droplets were observed around
cell nuclei in CMSCs stimulated in adipogenic differentiation medium (Fig 1Cii). CMSCs
aggregated into a three-dimensional spherical structure after approximately 24 h stimulation in
chondrogenic differentiation medium. Safranin O staining in sections taken from different
regions of the cell pellet after 3 weeks stimulation showed the presence of proteoglycans, which
are normally secreted into the extracellular matrix by cartilage cells (Fig 1Ciii). Control CMSCs
cultures maintained in the appropriate basal medium did not show evidence of differentiation
into these lineages (Fig 1Ci–1Ciii insets). DMSCs also differentiated into the osteogenic, adipo-
genic and chondrogenic mesenchymal lineages (Fig 2Ci, 2Cii and 2Ciii respectively) [13].
In vivo ectopic bone formation assay
CMSCs and DMSCs (n = 3 per group) were assayed for their capacity to develop bone-like tis-
sue following ectopic transplantation into SCID mice with HA/TCP particles as a vehicle. All
implants showed new bone formation throughout the implants. Fig 3A, 3B, 3E and 3F show
representative sections of CMSC and DMSC implants, respectively stained with H&E. The
H&E staining was performed with bright pink H&E staining is indicative of mineralized tissue
[17]. New bone was formed (area of pink staining) in HA/TCP (indicated by dashed lines) and
directly interfaces the ceramic surface. The new bone contains osteocytes embedded within the
matrix indicating that bone formation was active and progressive. Further histological exami-
nation showed that new bone formation was surrounded by the presence of adipocytes (honey-
comb-like structures), fibrous tissue, and small blood vessels. Anti-BrdU staining
demonstrated the presence of implanted cells associated with areas of mineral formation and
areas of dense fibrous tissue formation (Fig 3C, 3D, 3G and 3H). The transplanted CMSCs and
DMSCs exhibited the capacity to form mineralized and fibrous tissues in vivo.
Immunohistochemical staining with several osteogenesis markers was performed to con-
firm that cells with osteocyte properties were formed in the transplants. Implanted CMSCs and
DMSCs lining or embedded within the mineralized surfaces expressed the bone-related mark-
ers: BSP, OCN, OPN, and BGN (Fig 4A–4H). The reactivity of these markers showed that the
implanted CMSCs and DMSCs contributed to the generation of osteogenic cells. In addition,
the presence of newly formed vessels in the transplants was also indicated by immunostaining
with α-SMA (Fig 4I and 4J). Overall, the data demonstrated the presence of new bone forma-
tion with no obvious qualitative differences between CMSCs and DMSCs.
Discussion
We demonstrated the isolation and expansion of two different MSC populations obtained
from human term placenta, fetal-derived CMSCs and maternal-derived DMSCs. Both CMSCs
and DMSCs are shown to have typical MSC features: (a) adherence to plastic; (b) ability to dif-
ferentiate in vitro into adipocytes, osteocytes, and chondrocytes; and (c) expression of MSC
surface markers (CD90, CD146, CD166, CD44, CD73, and CD105). FISH analysis confirmed
that pure populations of fetal CMSCs and maternal DMSCs could be obtained using the isola-
tion methods employed. Thus, the CMSCs and DMSCs adhered to the criteria stipulated for
placental MSCs [2, 9].
differentiation into mesenchymal lineages. (i) Osteogenic differentiation, Alizarin Red staining in cells after 5weeks growth in osteogenic induction medium.
Arrows show calcium depositions. (ii) Adipogenic differentiation, Oil Red O staining in cells after 14 days growth in adipogenic induction medium. Arrows
show fat droplets. (iii) Chondrogenic differentiation, Safranin O staining for proteoglycans depositions in cells after 21 days growth in chondrogenic induction
medium. Inset shows control uninduced CMSCs. Scalebar is 100 μm.
doi:10.1371/journal.pone.0141246.g001
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Fig 2. DMSC phenotypic characterization. A. (i) Bright field microscopy image of DMSCs at P0. Magnification is 100X and scalebar is 100 μm. (ii) DMSCs
from placentae of male newborns were analyzed using interphase FISH on MSC nuclei. DMSCs showed two X chromosomes (Spectrum Green) signals.
Cell nuclei were stained blue with DAPI. Magnification is 630X. B. Primary DMSCs cell surface markers expression. Histograms of representative primary
DMSC at P3 depicting the expression of CD90, CD146, CD166, CD44, CD73, CD105, CD45, HLA-DR, and CD19. The red histogram shows the MSC
marker antibody staining while the white histogram shows the corresponding isotype control antibody staining. PE: phycoerythrin dye, APC: allophycocyanin
dye, APC-Cy7: allophycocyanin-Cy7 dye. C. Representative photomicrographs showing DMSCs differentiation into mesenchymal lineages. (i) Osteogenic
differentiation, Alizarin Red staining in cells after 5weeks growth in osteogenic induction medium. Arrows show calcium depositions. (ii) Adipogenic
Ectopic Bone Formation by Placenta-Derived Mesenchymal Stem Cells
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MSCs from different sources such as adipose tissue, bone marrow, and dental pulp have
been subjected to transplantation in the ectopic bone formation assay [14, 15, 25, 26]. This
study investigated CMSCs and DMSCs for the first time, and found that HA/TCP implanted
with these cells into the subcutaneous space of immunodeficient mice could differentiate into
new tissue with characteristics of bone. This indicates that donor MSCs has the capacity for
long-term survival and could contribute to the generation of different tissue types in vivo. The
efficacy of this in vivo assay was demonstrated in another study where HA/TCP were
implanted with human foreskin fibroblasts and HA/TCP only controls were tested and showed
only fibrous tissue growth with no indication of osteogenesis or haematopoiesis [26].
In this study, we set out to confirm that the implanted cells had survived and contributed to
tissue formation with BrdU staining. In principle, BrdU stain incorporates into the DNA of
dividing cells and diminishes as those cells further divide. Following 8 weeks post-implanta-
tion, a proportion of MSCs may have lost their BrdU expression due to their initial prolifera-
tion in vivo, or due to the physical location within tissue (i.e. osteocytes in lacunae), antigen
retrieval and DNA denaturing protocol may not have sufficiently exposed the antigen for its
detection by immunohistochemistry. Whilst we acknowledge the limitation of using BrdU to
detect implanted cells, this protocol has been widely used and accepted [27–29].
It is also of interest to note that development potential of BMMSCs in vivo was similar to
CMSCs and DMSCs in which the cells contributed to new bone formation together with sur-
rounding fibrous and adipocytes accumulation [14, 15, 30]. Our findings further support other
studies demonstrating placenta-derived MSCs in vivo osteogenesis capacity. Intrabone, but not
subcutaneous, injection of placenta adherent cells into a mouse model of myeloma-associated
bone loss promoted bone formation by stimulating differentiation of the host’s osteoblasts
[31]. Furthermore, placenta-derived MSCs grown in a silk fibroin/HA scaffold were trans-
planted in a rabbit radius defect model and improved bone repair as evidenced by formation of
new lamellar bone, trabecular bone and a number of osteoblasts [32]. In addition, there was
evidence of angiogenesis with evidence of new blood vessel formation. The presence of newly
formed vasculature is in agreement with previous studies that have reported dental pulp stem
cells when implanted using the similar in vivomouse model [14, 16]. Another study showed
amnion-derived MSCs promoted neovascularisation in an in vivomouse model [33].
Porous HA/TCP showed good tissue tolerance with no immunological or toxic reaction,
and that bone tissue could directly deposit upon their surfaces. This property is important for
bone graft substitutes because without it, fibrous tissue can intervene at the interface between
bone tissue and the graft, and cause loosening of the graft [12, 26]. The choice of osteoinductive
biomaterials (HA/TCP) combined with the appropriate choice of animal model are potentially
crucial to determine in vivo differentiation ability of CMSCs and DMSCs. To conclude, this is
the first evidence of in vivo differentiation potential of DMSCs and CMSCs following trans-
plantation in the mouse model of ectopic bone formation.
Conclusions
In this study, we have isolated human CMSCs and DMSCs and both cell types demonstrated
the characteristic MSC phenotype. Subcutaneous transplantation of CMSCs and DMSCs
embedded in a HA/TCP biomatrix, into a mouse model of ectopic bone formation led to the
formation of a bone-like structure. BrdU labelling indicated that transplanted cells were
differentiation, Oil Red O staining in cells after 14 days growth in adipogenic induction medium. Arrows show fat droplets. (iii) Chondrogenic differentiation,
Safranin O staining for proteoglycans depositions in cells after 21 days growth in chondrogenic induction medium. Inset shows control uninduced DMSCs.
Scalebar is 100 μm.
doi:10.1371/journal.pone.0141246.g002
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Fig 3. Histology of CMSCs and DMSCs transplants. Cross sections are representative of CMSCs transplants (A-B) and DMSCs transplants (E-F) after 8
weeks stained with Haematoxylin and Eosin (H&E). In the transplant, the HA/TCP carrier surfaces (dashed lines) are lined with new bone formation (b), areas
of immature bone (ob) together with the surrounding fibrous and hematopoietic tissue (a) and blood vessel (bv). Representative BrdU staining for localization
of implanted CMSCs (C-D) and DMSCs (G-H). BrdU-stained implanted cells were found lining the mineralized matrix (black arrows) and surrounding fibrous
tissue. Brown nuclear staining is indicative of DAB reactivity. There was no immunoreactivity present in sections stained with isotype-matched antibodies.
HA/TCP: hydroxyapatite/tricalcium phosphate particles. Magnification is 100X and scalebar is 500 μm.
doi:10.1371/journal.pone.0141246.g003
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Fig 4. Immunoreactivity of osteogenesis markers after in vivo transplantation of primary CMSCs and
DMSCs into immunocompromisedmice. (A-B) BGN: biglycan expression. (C-D) BSP: bone sialoprotein
expression. (E-F) OPN: osteopontin expression. (G-H) OCN: osteocalcin expression. (I-J) α-SMA: alpha-
smooth muscle actin as negative control. Inset shows representative control sections stained with isotype-
matched antibodies. Colour detection was performed using DAB reaction. Magnification is 200X and
scalebar is 300 μm. Black arrow show bone-forming surfaces and red arrows show blood vessels.
doi:10.1371/journal.pone.0141246.g004
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retained in the structure and contributed to tissue formation. Bone-specific markers such as
OPN, OCN, BGN, and BSP were present in both transplants without any qualitative difference.
These data suggest that human CMSCs and DMSCs have potent in vivo bone forming capacity
and may be worthwhile candidates for in vivo bone tissue repair.
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